Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Sanofi

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              CFRT 2020

              Participation Not Confirmed

              Update your events

              Sanofi Receives Health Canada Approval for Dupixent to Treat Severe Chronic Rhinosinusitis with Nasal Polyposis

              Contact the Supplier

              Lead Product(s): Dupilumab

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 18, 2020

              Details:

              Health Canada approved a new indication for Dupixent, as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.

              PharmaCompass__DigitalAd